

Are you a **WOMAN** or **GIRL** with hemophilia A or suspect you may live with it?

For women, girls, and people assigned female at birth with hemophilia A,

FLEXIBILITY FACTORS on your terms^a



Explore
2 OPTIONS
designed around
your lifestyle



esperoct®

*antihemophilic factor (recombinant),
glycopegylated-exei*

novoeight®

*Antihemophilic Factor
(Recombinant)*

You deserve a diagnosis and treatment options for your hemophilia.

^aPrior to reconstitution, Esperoct® and Novoeight® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

What is Novoeight® and Esperoct®?

Novoeight® (antihemophilic factor, recombinant) and Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] are injectable medicines used to treat, control, and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Novoeight® or Esperoct® when you have surgery

- Novoeight® and Esperoct® are not used to treat von Willebrand Disease

Important Safety Information

Who should not use Novoeight® or Esperoct®?

- You should not use Novoeight® or Esperoct® if you are allergic to factor VIII or any of the other ingredients of Novoeight® or Esperoct® or if you are allergic to hamster proteins

Please see additional Important Safety Information on next page. Please see Prescribing Information for Novoeight® [here](#) and Prescribing Information for Esperoct® [here](#).

Do you feel like your doctor is not listening to you?

Some women, girls, and people assigned female at birth have been told they do not have hemophilia, and they are only “carriers”



Recognizing and documenting your bleeds and symptoms


Tammy has hemophilia A and uses Esperoct®.



Identifying bleeds is important for self-advocacy

Signs and symptoms of hemophilia in women and girls should not be dismissed, especially when there is a history of hemophilia in the family. Record any pain, swelling, bruising, and bleeding you experience. Don't forget to take pictures and videos!

Hemophilia symptoms impact a woman's or girl's lifestyle at every stage of life. Talk to your doctor about the following or any other symptoms that do not feel normal to you:



Documenting your bleeds is important for you and your provider

You may find it hard to talk about your symptoms or know if your symptoms are unusual, but you deserve to be seen and heard. Document and share your bleeds and symptoms with your doctor. You know your body best, and it is important to self-advocate to receive the care you need.

Important Safety Information (cont'd)

What is the most important information I need to know about Novoeight® and Esperoct®?

- Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
- Call your healthcare provider or get emergency treatment right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, light-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

^aLonger than 10 minutes or need nasal packing/medical attention to control bleeding.

^bLonger than 7 days, changing pads/tampons every 2 hours or less, passing blood clots larger than 1 inch or the size of a quarter, requires double protection, or requires changing pad/tampon overnight.

Please see additional Important Safety Information on next page. Please see Prescribing Information for Novoeight® [here](#) and Prescribing Information for Esperoct® [here](#).


esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

novoeight®
Antihemophilic Factor (Recombinant)

Even if you have normal factor levels, they can change and you can still experience bleeds


- Although WFH guidance says that **women with hemophilia should be treated the same as men**, this may not be followed by all providers
- **About half of women and girls who are carriers for the hemophilia A gene, actually have hemophilia A** due to having Factor 8 levels below 50%, according to the NBDF
 - **Low factor levels** have been linked to an increased risk of bleeding, especially during menstruation and at the time of an accident, surgery, or childbirth

You are not alone



^aIn a real-world study of data collected from people receiving care in HTCs from 2012-2020.

Some women, girls, or people assigned female at birth **are unaware that they carry the gene** because there is no family history of hemophilia. **One-third of hemophilia cases** are considered spontaneous hemophilia.



HTC=hemophilia treatment center;
MASAC=Medical and Scientific Advisory Council;
NBDF=National Bleeding Disorders Foundation;
WFH=World Federation of Hemophilia.


Important Safety Information (cont'd)

What should I tell my healthcare provider before using Novoeight® or Esperoct®?

- Before taking Novoeight® or Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called “inhibitors” against Novoeight® or Esperoct®, which may stop Novoeight® and Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Novoeight® or Esperoct®**

Prioritize your health

Heavy periods, anemia, joint pain, and other challenging symptoms can be associated with women and girls who have hemophilia A.



- Missed work and school
- Interruptions to social life
- Financial cost
- Poor sleep
- Fatigue
- Mental health challenges

Recurring bleeds in muscles and joints may cause long-term damage:

- Chronic pain
- Chronic joint disease

Tammy has hemophilia A and uses Esperoct®.

“I heard thousands of times over the years that women can’t have hemophilia, and they can’t possibly be bleeding because their factor levels are normal. But I’m a woman who does have hemophilia.”

—Tammy, a woman living with hemophilia A who uses Esperoct®.

Please see additional Important Safety Information on next page. Please see Prescribing Information for Novoeight® [here](#) and Prescribing Information for Esperoct® [here](#).

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

novoeight®
Antihemophilic Factor (Recombinant)

Identifying your treatment needs

When talking to your doctor about treatment options, it is important to share bleed documentation and key information, such as your family history, so you can advocate for a personalized treatment plan. Here are some self-advocacy tips to have a productive conversation with your healthcare team.

Know when and how to **advocate for yourself**

GETTING STARTED

FOR EXAMPLE

"I'm considering a new treatment because even though I have mild hemophilia, I have been experiencing a lot of bleeding symptoms."

"I'm concerned about long-term risks of not having proper treatment as the focus is on my menstruation, but I'm experiencing other types of bleeding."

QUESTIONS YOU MIGHT WANT TO ASK:

"Will my factor levels change as I experience hormonal changes?"

"How much factor should I have on hand for treating the types of bleeds I am experiencing?"

LIST ANY CHANGES SINCE YOUR LAST VISIT

FOR EXAMPLE

"My daily activities have changed since my last visit."

"My period is 10 days long and heavy, as shown in my tracker. What steps can we take to resolve this?"

"I've noticed bruises on my body and have swelling in my _____."

MAKE A LIST OF THINGS TO BRING

FOR EXAMPLE

- Reasons why you think that treatment could be a good option
- Documentation such as your logbook and/or photos of bleeds or symptoms
- A record of your menstrual bleeding or any changes in the amount of bleeding
- A list of lifestyle changes that may affect your current treatment

EXPLAIN WHY MAKING A CHANGE MATTERS TO YOU

FOR EXAMPLE

"I want to feel protected with factor on hand in case of bleeding emergencies."

"I'm concerned about my long-term health without bleed treatment."

Important Safety Information (cont'd)

What are the possible side effects of Novoeight® and Esperoct®?

- Novoeight®:** Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever
- Esperoct®:** Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

You control your treatment journey



Ask about Esperoct® or Novoeight®


Factor 8 therapies designed around your lifestyle

esperoct®

When you need bleed protection with a treatment that can be dosed less often and **fits into your lifestyle**.^{a,b}

novoeight®

When you need **on-the-go bleed protection** with a treatment that can also help you stick to your treatment goals.^{a,c}



- The lines in the graph above represent the levels of Factor 8 in your blood over time
- Novoeight® levels are highest on the day you take it, then slowly decrease until it is time to dose again
- Esperoct® levels are also highest on the day you take it. Because Esperoct® has an extended half-life, it lasts longer in the blood and slowly decreases until it is time to dose again 4 days later

^aPrior to reconstitution, Esperoct® and Novoeight® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

^bEsperoct® is an EHL treatment that is approved for prophylaxis every 4 days for adults and adolescents. Please see Prescribing Information for complete dosing information.

^cNovoeight® is an SHL treatment that is approved for prophylaxis every other day or 3 times weekly. Please see Prescribing Information for complete dosing information.

^dDose-escalation trial in 26 previously treated adult patients with severe hemophilia A who received 1 of 3 doses of Esperoct®. Each dose escalation was preceded by safety and pharmacokinetic assessments. Data shown is from a 50 IU/kg dose of Esperoct®. Blood was sampled during a 168-hour period post dose.

^eData from 5 clinical trials of 48 adult/adolescent previously treated patients with severe hemophilia A. The pharmacokinetics were assessed following a wash-out period and a subsequent single intravenous 50 IU/kg dose of NovoEight®. Blood was sampled during a 48-hour period post dose.

EHL=extended half-life; SHL=standard half-life.

Please see additional Important Safety Information on next page. Please see Prescribing Information for Novoeight® [here](#) and Prescribing Information for Esperoct® [here](#).

esperoct®
antihemophilic factor (recombinant), glycopegylated-exe

novoeight®
Antihemophilic Factor (Recombinant)

esperoct[®]

antihemophilic factor (recombinant),
glycopegylated-exei

The EHL FLEXIBILITY FACTOR^a

BLEED PROTECTION you deserve



EHL (extended half-life):
The treatment is designed to **stay in the body longer**, so it can be taken less often.

The only **EHL** product
that can go with you up to both



104 °F for up to
3 MONTHS and **86 °F** for up to
12 MONTHS

**EFFECTIVE
BLEED CONTROL**

1.2

overall bleeds per year
(median ABR)
for adults and
adolescents with
severe hemophilia A
aged 12 and older
(n=175)^b

An **extended half-life
Factor 8 treatment** that can
be used as prophylaxis or on demand



Established safety profile

Studied in **1 of the largest and longest clinical trial programs** with 270 previously treated patients for more than 105,000 infusion days

- 0 blood clots and 0 PEG-related safety concerns
- One previously treated patient with a high-risk genetic variation developed an inhibitor to Factor 8^c
 - Similar to the reported rate in patients with severe hemophilia A



Average half-life in adults^d

Esperoct[®] is made by taking the existing Novoeight[®] Antihemophilic Factor (Recombinant) molecule and adding PEGylation technology to **extend the half-life**



Bleed control

In a clinical trial of Esperoct[®], **97% of all bleeds were controlled** with 1 to 2 doses^e



For women and girls
of ALL ages with
hemophilia A



**After reconstitution,
Esperoct[®] can be:**



Used for up to 4 HOURS
at up to 86 °F

OR



Stored in a refrigerator
between 36 °F and 46 °F
for up to 24 HOURS



Administration

Preparing an infusion
is fast: Just **ATTACH,
TWIST, and MIX**
with MixPro[®]

^aPrior to reconstitution, Esperoct[®] can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

^bData shown are from the main phase study of 175 previously treated people aged 12 and older with severe hemophilia A who received Esperoct[®] 50 IU/kg every 4 days for 76 weeks.

^cAn 18-year-old African American male developed an inhibitor after 93 infusion days of Esperoct[®]. The inhibitor rose to 13.5 Bethesda units and the patient stopped participation in the study. There was no change in efficacy, and the inhibitor eventually went away on its own (without use of immune tolerance induction therapy).

^dData shown are from 42 adults who received a pharmacokinetic assessment around the first Esperoct[®] 50 IU/kg dose.

^eData shown are from a study where 12 adult and adolescent PTPs with severe hemophilia chose to be treated on demand and received Esperoct[®] for 532 bleeding episodes. PTP=previously treated patient.

“I really like the fact that Esperoct[®] is stable at room temperature up to 104 degrees. I can just throw it in my backpack and go and then if I need to stop and infuse, I can do that.”

—Tammy, a woman living with hemophilia A who uses Esperoct[®].

ABR=annualized bleeding rate.



To learn more, visit esperoct.com

Important Safety Information (cont'd)

Who should not use Novoeight[®] or Esperoct[®]?

- You should not use Novoeight[®] or Esperoct[®] if you are allergic to factor VIII or any of the other ingredients of Novoeight[®] or Esperoct[®] or if you are allergic to hamster proteins

Please see additional Important Safety Information on next page. Please see Prescribing Information for Novoeight[®] [here](#) and Prescribing Information for Esperoct[®] [here](#).

esperoct[®]

antihemophilic factor (recombinant),
glycopegylated-exei



SHL (standard half-life):
The treatment is taken 3 to 4 times a week and can be used to treat bleeds when they happen.

The SHL FLEXXIBILITY FACTOR^a

BLEED CONTROL you deserve

A **standard half-life Factor 8 treatment** that can be used as prophylaxis or on demand



Established safety profile

- 0 inhibitors were confirmed in one of the largest Factor 8 clinical trials to date, with 242 previously treated people receiving more than 130,000 infusions^b
 - In a clinical trial of previously untreated patients, 42.9% developed inhibitors
- **Safety results were consistent among adults, adolescents, and children**
- **No blood clots occurred during the trials**

^aPrior to reconstitution, Novoeight® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

^bPeople with previous inhibitors and those new to treatment were not included in the trial. People with hemophilia A may develop inhibitors to Factor 8.

Important Safety Information (cont'd)

What is the most important information I need to know about Novoeight® and Esperoct®?

- Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
- Call your healthcare provider or get emergency treatment right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, light-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

The only SHL product that can go with you up to both




104 °F for up to **3 MONTHS** and **86 °F** for up to **12 MONTHS**

RELIABLE BLEED CONTROL

89%

of bleeds controlled with 1 or 2 doses in adolescents and adults with severe hemophilia A aged 12 to 65 years (N=150)



For women and girls of ALL ages with hemophilia A



Administration

Preparing an infusion is fast: Just **ATTACH, TWIST, and MIX** with MixPro®

“I have had a good experience with Novoeight®. Anytime that I’ve had a bleed, I have been able to administer the product, and it has done its job for me.”

—Elsie, a woman living with hemophilia A who uses Novoeight®.



To learn more, visit novoeight.com

Please see additional Important Safety Information on next page. Please see Prescribing Information for Novoeight® [here](#) and Prescribing Information for Esperoct® [here](#).



esperoct®
antihemophilic factor (recombinant),
glycopegylated-exei

novoeight®
Antihemophilic Factor
(Recombinant)



Your needs as a **WOMAN** are important

Your doctor is the clinical expert,
but you are the expert on your experience.
Work together to choose the right treatment for you.

Here are some questions and concerns to discuss at your next appointment:

- I am concerned about my long-term health without bleed treatment
- Can we talk through my treatment concerns?
- Would an EHL like Esperoct® or an SHL like Novoeight® work best for my needs?
- I am not sure what you mean. Could you please explain that in a simpler way?
- Who should I contact if I have questions between appointments?

Name: _____

Contact information: _____

Your needs are important and you deserve to be heard because you are worth it.

Important Safety Information (cont'd)

What should I tell my healthcare provider before using Novoeight® or Esperoct®?

- Before taking Novoeight® or Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called “inhibitors” against Novoeight® or Esperoct®, which may stop Novoeight® and Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Novoeight® or Esperoct®**



Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Esperoct® and Novoeight® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2025 Novo Nordisk All rights reserved. US25HRBD00011 February 2025

Esperoct® or Novoeight®
could be right for you.
To learn more, **connect** with a
Rare Blood Community Liaison

